Huerth, Germany

Bernd Neumaier

This inventor holds 2 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignees: Universität Zu Koln, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernd Neumaier. Retrieved from https://idiyas.com/inventor/bernd-neumaier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Hurth, DE (2018)
  • Cologne, DE (2023)

Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Bernd Neumaier: Innovator in Imaging Probes

Introduction

Bernd Neumaier is a notable inventor based in Hurth, Germany, recognized for his contributions to the field of imaging probes. With a total of two patents, his work focuses on enhancing the visualization of prostate-specific membrane antigen (PSMA) expressing tissues, which is crucial for the diagnosis of prostate cancer.

Latest Patents

Neumaier's latest patents include innovative compounds such as 2-alkoxy-6-[18F]fluoronicotinoyl substituted lys-c(O)-glu derivatives. These compounds have been identified as efficient imaging probes for PSMA expressing tissues, outperforming other known PSMA specific ligands. The 6-[F]fluoro-2-alkoxy and 6-[F]fluoro-4-alkoxy substituted analogs demonstrated significant differences in cellular uptake in PSMA expressing prostate tumor cells. The 2-alkoxy derivative exhibited higher cellular uptake values compared to [F]DCFPyL, while the 4-alkoxy derivative showed lower uptake. In vivo PET studies revealed that the 2-alkoxy-substituted probes provided excellent visualization of PSMA positive ganglia, making them valuable for diagnosing small prostate cancer lesions. Additionally, Neumaier developed efficient methods for producing 18F-labeled active esters, which are essential for creating PSMA-specific PET tracers.

Career Highlights

Throughout his career, Neumaier has worked with prestigious institutions such as the Max Planck Society for the Advancement of Science and the University of Cologne. His research has significantly advanced the field of medical imaging, particularly in the context of prostate cancer diagnosis.

Collaborations

Neumaier has collaborated with notable colleagues, including Boris Zlatopolskiy and Raphael Richarz, contributing to the development of innovative imaging techniques.

Conclusion

Bernd Neumaier's work in the field of imaging probes has made a significant impact on the diagnosis of prostate cancer. His innovative patents and collaborations highlight his dedication to advancing medical imaging technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…